tecastemizole has been researched along with cisapride in 8 studies
Studies (tecastemizole) | Trials (tecastemizole) | Recent Studies (post-2010) (tecastemizole) | Studies (cisapride) | Trials (cisapride) | Recent Studies (post-2010) (cisapride) |
---|---|---|---|---|---|
18 | 0 | 3 | 1,554 | 390 | 110 |
Protein | Taxonomy | tecastemizole (IC50) | cisapride (IC50) |
---|---|---|---|
5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.767 | |
3-hydroxy-3-methylglutaryl-coenzyme A reductase | Homo sapiens (human) | 3.37 | |
Cytochrome P450 3A4 | Homo sapiens (human) | 0.3 | |
5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0098 | |
Alpha-2A adrenergic receptor | Homo sapiens (human) | 3.5923 | |
Cytochrome P450 2D6 | Homo sapiens (human) | 0.07 | |
Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 0.1701 | |
D(2) dopamine receptor | Homo sapiens (human) | 0.35 | |
Dipeptidyl peptidase 4 | Rattus norvegicus (Norway rat) | 2.69 | |
5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0098 | |
Insulin receptor | Rattus norvegicus (Norway rat) | 3.37 | |
Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 2.29 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 3.3827 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 3.26 | |
D | Rattus norvegicus (Norway rat) | 0.0065 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 3.6495 | |
Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0065 | |
D(1A) dopamine receptor | Homo sapiens (human) | 1.7 | |
Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0065 | |
Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0065 | |
Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 2.29 | |
Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 0.0065 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.083 | |
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0054 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.2597 | |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 3.6495 | |
5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 4.47 | |
5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 4.47 | |
5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0098 | |
Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.384 | |
Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.03 | |
Prostaglandin G/H synthase 2 | Homo sapiens (human) | 3.37 | |
Alpha-1B adrenergic receptor | Homo sapiens (human) | 0.03 | |
D(3) dopamine receptor | Homo sapiens (human) | 0.144 | |
5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | 0.9 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.0407 | |
Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 2.29 | |
D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.535 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.2536 | |
Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | 0.1701 | |
Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.994 | |
5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | 0.9 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 8 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M | 1 |
Keserü, GM | 1 |
Li, J; Rajamani, R; Reynolds, CH; Tounge, BA | 1 |
Bianucci, AM; Calderone, V; Coi, A; Massarelli, I; Testai, L | 1 |
Jia, L; Sun, H | 1 |
Caron, G; Ermondi, G; Visentin, S | 1 |
Brown, AM; Ficker, E; Obejero-Paz, CA; Zhao, S | 1 |
Paakkari, I | 1 |
1 review(s) available for tecastemizole and cisapride
Article | Year |
---|---|
Cardiotoxicity of new antihistamines and cisapride.
Topics: Arrhythmias, Cardiac; Astemizole; Benzimidazoles; Butyrophenones; Cetirizine; Cisapride; Heart Diseases; Histamine H1 Antagonists; Humans; Loratadine; Piperidines; Serotonin Receptor Agonists; Terfenadine; Triprolidine | 2002 |
7 other study(ies) available for tecastemizole and cisapride
Article | Year |
---|---|
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2002 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A two-state homology model of the hERG K+ channel: application to ligand binding.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Ligands; Models, Biological; Models, Molecular; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation | 2005 |
Identification of "toxicophoric" features for predicting drug-induced QT interval prolongation.
Topics: Amino Acid Sequence; Heart; Humans; Models, Molecular; Molecular Sequence Data; Molecular Structure; Protein Subunits; Sequence Alignment; Structure-Activity Relationship; Trans-Activators; Transcriptional Regulator ERG | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship | 2009 |
The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations.
Topics: Anti-Arrhythmia Agents; Astemizole; Benzimidazoles; Binding Sites; Blotting, Western; Cation Transport Proteins; Cell Line; Cell Membrane; Cisapride; DNA-Binding Proteins; Dose-Response Relationship, Drug; Electrophysiology; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Gastrointestinal Agents; Histamine H1 Antagonists; Humans; Inhibitory Concentration 50; Ions; Long QT Syndrome; Models, Chemical; Mutagenesis, Site-Directed; Mutation; Patch-Clamp Techniques; Piperidines; Potassium Channels; Potassium Channels, Voltage-Gated; Protein Folding; Pyridines; Quaternary Ammonium Compounds; Quinidine; Structure-Activity Relationship; Trans-Activators; Transcriptional Regulator ERG | 2002 |